For years, dermatologists and plastic surgeons have been injecting filler into the temple area off-label. This means injectors are using fillers that aren’t indicated and safety-tested for the temple area specifically. However, there’s exciting news from Allergan Aesthetics today: Juvéderm Voluma is the first and only hyaluronic acid filler to receive FDA approval for the improvement of moderate-to-severe temple hollowing in patients 21 and older.
How Juvéderm Voluma Works in the Temples
According to Allergan Aesthetics, Juvéderm Voluma temporarily adds volume to immediately lift and augment the shape, contour and structure of the temple. This creates a smooth transition from the cheekbone to the forehead, which provides balance to the patient’s overall facial shape. With the natural aging process, the temples can take on a bit of a sunken look. Filling the area can make the face look more youthful and balanced. “This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face, and it addresses a real unmet need for patients,” says Carrie Strom, president of Allergan Aesthetics and senior vice president of AbbVie.
The Clinical Study
In a clinical study, more than 80 percent of participants had at least a one-point improvement in moderate-to-severe temple hollowing three months after treatment. The improvement also lasted for more than one year. The results also revealed that more than 85 percent of people were satisfied with how “balanced, well-proportioned and symmetric” their face looked three months post-treatment. The majority of participants also commented on how “rested their face appeared” and “how youthful their temples made them look.” New Orleans dermatologist Deirdre Hooper, MD, a clinical trial investigator for this new indication, says, “In the clinical study, we found that patients said they looked an average of five years younger six months after treatment.”
